The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Many Americans have turned to Hims & Hers and other telehealth companies for copies of weight-loss drugs after struggling to ...

Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims & Hers (HIMS) stock dips as Morgan Stanley downgrades the telehealth firm citing its recent rally in share price. Read more here.

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

Yeezy isn’t the only company being called out for its “bait-and-switch” Super Bowl commercial, a Californian company called ...

Shares of Hims & Hers Health (HIMS) are down at the time of writing after Morgan Stanley, led by four-star analyst Craig Hettenbach, ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.